Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease.

Neurobiology of disease - 1 Jan 2006

Hockly Emma, Tse Jamie, Barker Amy L, Moolman Donna L, Beunard Jean-Luc, Revington Adrian P, Holt Kim, Sunshine Sunny, Moffitt Hilary, Sathasivam Kirupa, Woodman Benjamin, Wanker Erich E, Lowden Philip A S, Bates Gillian P

Abstract excerpt

Huntington's disease (HD) is an inherited progressive neurological disorder for which there is no effective therapy. It is caused by a CAG/polyglutamine repeat expansion that leads to abnormal protein aggregation and deposition in the brain. Several compounds have been shown to disrupt the aggregation process in vitro, including a number of benzothiazoles. To further explore the therapeutic potential of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzothiazoles
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Huntington Disease

Share to Mice, Inbred CBA

Share to Mice, Transgenic

Share to Neuroprotective Agents

Share to Organ Culture Techniques

Share to Thiazoles

Source

Identifiers

PMID: 16111888
DOI: 10.1016/j.nbd.2005.07.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease.PMID 16111888Read ↗

Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assaySemantic proximity Read ↗

Discovery of 2-Aminothiazoles as Potent Antiprion CompoundsSemantic proximity Read ↗

Therapy development in Huntington disease: From current strategies to emerging opportunitiesSemantic proximity Read ↗

Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's diseaseSemantic proximity Read ↗

Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis.Semantic proximity Read ↗

Minocycline and doxycycline are not beneficial in a model of Huntington's disease.Semantic proximity Read ↗

New Directions in Therapeutics for Huntington DiseaseSemantic proximity Read ↗

Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model.Semantic proximity Read ↗

In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice.Semantic proximity Read ↗

Inhibition of Polyglutamine Aggregation in R6/2 HD Brain Slices—Complex Dose–Response ProfilesSemantic proximity Read ↗

Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidatesSemantic proximity Read ↗

A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.